SEC Form 4 · accession 0001209191-18-008418
Karyopharm Therapeutics Inc. · KPTI
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Michael Kauffman
Officer — Chief Executive Officer · Director
Period of report
Feb 7, 2018
Accepted (ET)
Feb 8, 2018 · 4:08 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001503802
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Feb 7, 2018 | M | 10,000 | $0.264 | A | 723,510 | I | By Spouse |
| Common StockF2 | Feb 7, 2018 | S | 10,000 | $12.5048 | D | 713,510 | I | By Spouse |
| Common Stock | holding | — | — | — | 512,143 | D | ||
| Common StockF3 | holding | — | — | — | 47,309 | I | By GRAT | |
| Common StockF4 | holding | — | — | — | 47,309 | I | By Spouse's GRAT |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F5 | $0.264 | Feb 7, 2018 | M | 10,000 | D | — | Dec 13, 2021 | Common Stock | 10,000 | 9,394 | I |
Explanation of responses
- F1These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the spouse of the reporting person.
- F2Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $12.40 to $12.67, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
- F3These shares are held by the Michael G. Kauffman 2016 Qualified Annuity Interest Trust.
- F4These shares are held by the Sharon Shacham 2016 Qualified Annuity Interest Trust.
- F5This option, representing a right to purchase a specified number of shares, vested as to 25% of the shares on December 12, 2012, and the remaining 75% vested in 36 equal monthly installments thereafter.